© 2022 MJH Life Sciences and Pharmacy Times – Pharmacy Practice News and Expert Insights. All rights reserved.
© 2022 MJH Life Sciences™ , Pharmacy Times – Pharmacy Practice News and Expert Insights. All rights reserved.
February 16, 2017
To help prevent and treat neutropenia, we routinely use Granulocyte Colony Stimulating Factors (G-CSF) for patients undergoing myelosuppressive chemotherapy.
February 02, 2017
Application pulled for biosimilar that treats neutropenia.
June 09, 2016
Granix is a human granulocyte factor produced in a bioreactor using recombinant DNA technology.
September 20, 2015
The FDA is changing dispensing requirements for the schizophrenia drug clozapine (Clozaril) to address safety concerns about severe neutropenia.
September 03, 2015
The first biosimilar to receive FDA approval is now available the United States.
July 03, 2015
Chemotherapy-induced neutropenia (CIN) is a common adverse occurrence in patients treated for solid tumors.
Specialty and community pharmacies more involved in cancer treatment.
March 06, 2015
After years of debate and regulatory hurdles, a milestone was achieved today when the FDA approved the first biosimilar in the United States.
December 30, 2014
Teva's Granix Injection has been approved by the FDA for self-administration by patients and caregivers.
November 18, 2013